Deborah Kilpatrick, PhD

A member of the Material Impact entrepreneurial advisory board since Material Impact Fund I, Deborah Kilpatrick, Ph.D. is the co-founder and CEO of Evidation Health, a digital health company backed by B Capital Group, GE Ventures, Sanofi Ventures, AMV, and Rock Health. 

Evidation is focused on quantifying real-world clinical and economic impact in the digital era of medicine, helping its partners optimize health outcomes in connected populations outside clinic walls.

Previously, Deborah was the Chief Commercial Officer of genomic diagnostics company CardioDx, which was named in the Wall Street Journal Technology Innovation Awards, TIME Magazine’s Top 10 Medical Breakthroughs, and the Edison Awards. Earlier in her career, Deborah held multiple leadership roles at Guidant Corporation’s Vascular Intervention Division, including Research Fellow, Director of R&D, and Director of New Ventures.  She chairs the Georgia Tech College of Engineering Advisory Board, sits on the Leadership Board for Santa Clara University’s College of Arts and Sciences in Silicon Valley, and is a Fellow of the American Institute of Medical and Biological Engineering.

Deborah is a co-founder of the MedtechVision Conference now held annually in Silicon Valley, and she has been named to FierceBiotech’s Top Women in Biotech, FierceMedicalDevice’s Top Women in Medtech, and Silicon Valley Business Journal’s 100 Women of Influence.